On Monday, Travere Therapeutics Inc (NASDAQ: TVTX) opened lower -0.14% from the last session, before settling in for the closing price of $14.01. Price fluctuations for TVTX have ranged from $5.12 to $15.36 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 3.07% over the past five years. Company’s average yearly earnings per share was noted -131.22% at the time writing. With a float of $75.34 million, this company’s outstanding shares have now reached $75.37 million.
Let’s look at the performance matrix of the company that is accounted for 380 employees.
Travere Therapeutics Inc (TVTX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Travere Therapeutics Inc is 1.51%, while institutional ownership is 117.55%. The most recent insider transaction that took place on Sep 30 ’24, was worth 562,324. In this transaction Director of this company sold 40,000 shares at a rate of $14.06, taking the stock ownership to the 81,000 shares. Before that another transaction happened on Sep 30 ’24, when Company’s Director proposed sale 40,000 for $14.06, making the entire transaction worth $562,324.
Travere Therapeutics Inc (TVTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -131.22% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Check out the current performance indicators for Travere Therapeutics Inc (TVTX). In the past quarter, the stock posted a quick ratio of 2.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.84, a number that is poised to hit -0.62 in the next quarter and is forecasted to reach -1.19 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Travere Therapeutics Inc (NASDAQ: TVTX) saw its 5-day average volume 2.0 million, a positive change from its year-to-date volume of 1.32 million. As of the previous 9 days, the stock’s Stochastic %D was 35.08%. Additionally, its Average True Range was 0.83.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 85.35%, which indicates a significant increase from 60.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.86% in the past 14 days, which was lower than the 63.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.75, while its 200-day Moving Average is $8.56. Nevertheless, the first resistance level for the watch stands at $14.37 in the near term. At $14.74, the stock is likely to face the second major resistance level. The third major resistance level sits at $15.08. If the price goes on to break the first support level at $13.66, it is likely to go to the next support level at $13.32. Assuming the price breaks the second support level, the third support level stands at $12.95.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
There are currently 76,129K shares outstanding in the company with a market cap of 1.07 billion. Presently, the company’s annual sales total 145,240 K according to its annual income of -111,400 K. Last quarter, the company’s sales amounted to 54,120 K and its income totaled -70,410 K.
